Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests", and for other purposes.
Client: CHIPPS, CAFFREY AND DUBILIER, P. S. C. · Firm: GABBERT CONSULTING CO LLC
Supported HR 1463 a bill that restricts funding for FDA's LDT ruling
Saving Access to Laboratory Services Act
Client: CHIPPS, CAFFREY AND DUBILIER, P. S. C. · Firm: GABBERT CONSULTING CO LLC
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
CHIPPS, CAFFREY AND DUBILIER, P. S. C. via GABBERT CONSULTING CO LLC
2025 · third_quarter · 3T
Lobbyed against medicaid cuts in the Big Beautiful Bill Met with VA to discuss benefits of outsourcing Pathology
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
CHIPPS, CAFFREY AND DUBILIER, P. S. C. via GABBERT CONSULTING CO LLC
2025 · second_quarter · 2A
Source: Senate LDA
CMS Reimbursement Cuts/ HR 2377
Saving Access to Laboratory Services Act
Client: CHIPPS, CAFFREY AND DUBILIER, P. S. C. · Firm: GABBERT CONSULTING CO LLC
CMS Reimbursement Cuts/ HR 2377 Saving Access to Laboratory Services Act This bill modifies provisions relating to Medicare payment rates for clinical diagnostic laboratory services, including by requiring payment rates for certain widely available clinical diagnostic laboratory tests to be based on a statistical sampling of private sector rates.
Saving Access to Laboratory Services Act
Client: CHIPPS, CAFFREY AND DUBILIER, P. S. C. · Firm: GABBERT CONSULTING CO LLC
CMS Reimbursement Cuts/ HR 2377 Saving Access to Laboratory Services Act This bill modifies provisions relating to Medicare payment rates for clinical diagnostic laboratory services, including by requiring payment rates for certain widely available clinical diagnostic laboratory tests to be based on a statistical sampling of private sector rates.
Saving Access to Laboratory Services Act
Client: CHIPPS, CAFFREY AND DUBILIER, P. S. C. · Firm: GABBERT CONSULTING CO LLC
CMS Reimbursement Cuts/ HR 2377
Saving Access to Laboratory Services Act
Client: CHIPPS, CAFFREY AND DUBILIER, P. S. C. · Firm: GABBERT CONSULTING CO LLC
CMS Reimbursement Cuts/ HR 2377 Saving Access to Laboratory Services Act This bill modifies provisions relating to Medicare payment rates for clinical diagnostic laboratory services, including by requiring payment rates for certain widely available clinical diagnostic laboratory tests to be based on a statistical sampling of private sector rates.
Saving Access to Laboratory Services Act
Client: CHIPPS, CAFFREY AND DUBILIER, P. S. C. · Firm: GABBERT CONSULTING CO LLC
CMS Reimbursement Cuts/ HR 2377
Saving Access to Laboratory Services Act
Client: CHIPPS, CAFFREY AND DUBILIER, P. S. C. · Firm: GABBERT CONSULTING CO LLC
CMS Reimbursement Cuts/ HR 2377
Saving Access to Laboratory Services Act
Client: CHIPPS, CAFFREY AND DUBILIER, P. S. C. · Firm: GABBERT CONSULTING CO LLC
CMS Reimbursement Cuts/ HR 2377
Lobbyed against medicaid cuts in the Big Beautiful Bill
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIPPS, CAFFREY AND DUBILIER, P. S. C. via GABBERT CONSULTING CO LLC
2025 · second_quarter · Q2
Lobbyed against medicaid cuts in the Big Beautiful Bill
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIPPS, CAFFREY AND DUBILIER, P. S. C. via GABBERT CONSULTING CO LLC
2025 · first_quarter · Q1
Supported HR 1463 a bill that restricts funding for FDA's LDT ruling
Filing targets: HOUSE OF REPRESENTATIVES
CHIPPS, CAFFREY AND DUBILIER, P. S. C. via GABBERT CONSULTING CO LLC
2024 · fourth_quarter · Q4
CMS Reimbursement Cuts/ HR 2377 Saving Access to Laboratory Services Act This bill modifies provisions relating to Medicare payment rates for clinical diagnostic laboratory services, including by requiring payment rates for certain widely available clinical diagnostic laboratory tests to be based on a statistical sampling of private sector rates.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIPPS, CAFFREY AND DUBILIER, P. S. C. via GABBERT CONSULTING CO LLC
2024 · third_quarter · Q3
CMS Reimbursement Cuts/ HR 2377 Saving Access to Laboratory Services Act This bill modifies provisions relating to Medicare payment rates for clinical diagnostic laboratory services, including by requiring payment rates for certain widely available clinical diagnostic laboratory tests to be based on a statistical sampling of private sector rates.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIPPS, CAFFREY AND DUBILIER, P. S. C. via GABBERT CONSULTING CO LLC
2024 · second_quarter · Q2
CMS Reimbursement Cuts/ HR 2377 Saving Access to Laboratory Services Act This bill modifies provisions relating to Medicare payment rates for clinical diagnostic laboratory services, including by requiring payment rates for certain widely available clinical diagnostic laboratory tests to be based on a statistical sampling of private sector rates.
FDA issues final rule applying medical device rules to laboratory developed tests
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIPPS, CAFFREY AND DUBILIER, P. S. C. via GABBERT CONSULTING CO LLC
2024 · first_quarter · 1A
CMS Reimbursement Cuts/ HR 2377
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIPPS, CAFFREY AND DUBILIER, P. S. C. via GABBERT CONSULTING CO LLC
2024 · first_quarter · Q1
CMS Reimbursement Cuts/ HR 2377
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIPPS, CAFFREY AND DUBILIER, P. S. C. via GABBERT CONSULTING CO LLC
2023 · fourth_quarter · 4A
CMS Reimbursement Cuts/ HR 2377
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIPPS, CAFFREY AND DUBILIER, P. S. C. via GABBERT CONSULTING CO LLC
2023 · fourth_quarter · Q4
CMS Reimbursement Cuts/ HR 2377
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIPPS, CAFFREY AND DUBILIER, P. S. C. via GABBERT CONSULTING CO LLC
2023 · third_quarter · Q3
CMS Reimbursement Cuts/ HR 2377
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIPPS, CAFFREY AND DUBILIER, P. S. C. via GABBERT CONSULTING CO LLC
2023 · third_quarter · RR
Medicaid/Medicare reimbursement rates, eligibility criteria, and coverage policies, insurance regulations, decisions related to the sharing and utilization of health data, grants and funding opportunities for rural healthcare providers, and grants and funding opportunities for technology and innovation in healthcare
Medicaid/Medicare reimbursement rates, eligibility criteria, and coverage policies, insurance regulations, decisions related to the sharing and utilization of health data, grants and funding opportunities for rural healthcare providers, and grants and funding opportunities for technology and innovation in healthcare
PATHOLOGY AND CYTOLOGY LABORATORIES, INC. via GABBERT CONSULTING CO LLC
2023 · third_quarter · RR
CMS, insurance, healthcare, clinical labs
CMS, insurance, healthcare, clinical labs
CMS, insurance, healthcare, clinical labs
SPACE TANGO via GABBERT CONSULTING CO LLC
2020 · first_quarter · Q1
Looking at Department of Energy's goals for Space
Monitoring NASA and DoE Budget
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, Natl Aeronautics & Space Administration (NASA), SENATE
SPACE TANGO via GABBERT CONSULTING CO LLC
2019 · fourth_quarter · Q4
Monitoring NASA and DoE Budget
Looking at Deptartment of Energy's goals for Space
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, Natl Aeronautics & Space Administration (NASA), SENATE
SPACE TANGO via GABBERT CONSULTING CO LLC
2019 · second_quarter · RR
Working on issues that help commercialize space. Anticipate getting involved in mining/environmental issues.
Working on issues that help commercialize space. Anticipate getting involved in mining/environmental issues.
Working on issues that help commercialize space. Anticipate getting involved in mining/environmental issues.
Medicaid/Medicare reimbursement rates, eligibility criteria, and coverage policies, insurance regulations, decisions related to the sharing and utilization of health data, grants and funding opportunities for rural healthcare providers, and grants and funding opportunities for technology and innovation in healthcare
Medicaid/Medicare reimbursement rates, eligibility criteria, and coverage policies, insurance regulations, decisions related to the sharing and utilization of health data, grants and funding opportunities for rural healthcare providers, and grants and funding opportunities for technology and innovation in healthcare